Aprea Therapeutics Reports Q2 2023 Net Loss of $3.26 Million

Aprea Therapeutics, Inc.(APRE), a biopharmaceutical company fo cused on developing novel cancer therapies, has released its unaudited condensed consolidated financial statements for the second quarter of 2023. The company reported a net loss of $3.26 million for the quarter, accompanied by grant revenue of $249,688. Despite the operating expenses incurred during the period, Aprea Therapeutics continues to advance its mission of pioneering innovative treatments for cancer.

Current Asset Position

The company's financial snapshot as of June 30, 2023, revealed that Aprea Therapeutics holds cash and cash equivalents amounting to $27.68 million, a slight decrease from the $28.79 million reported at the end of 2022. Additionally, prepaid expenses and other current assets were valued at $953,670, compared to $1.37 million in the previous year. The total current assets for the quarter were reported at $28.64 million, showing a decrease from the $30.15 million reported at the close of 2022.

Liabilities and Equity